There is no vaccine yet, but the National Institutes of Health has entered
the first phase of clinical trials for an investigational vaccine.
«
The first phase of clinical trials are tests of human safety, so this is a promising start,» Alvey said.
Not exact matches
In a research and strategy update, Novo said it will initiate a
phase 3
clinical trial program with once - weekly subcutaneous semaglutide in obesity in the
first half
of 2018.
In a research and strategy update, Novo said it planned to start a final
phase 3
clinical trial program with once - weekly subcutaneous semaglutide in obesity in the
first half
of 2018.
Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class
of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the
first patient in its
Phase 1b
clinical trial of light - activated AU - 011, an investigational,
first - in - class targeted therapy in development for the treatment
of ocular melanoma, a rare and life - threatening disease.
The
phase 1
clinical trial is the
first to test the functional replacement
of the mutated gene responsible for SMA1.
Promising results
of an earlier, initial, multicenter
clinical trial of nivolumab,
first reported in 2013 and directed by Brahmer, led to the current
phase III
trial of 260 patients treated at hospitals across the world.
In March, researchers, in collaboration with the pharmaceutical company Ultragenyx, completed the
first part
of a
Phase III
clinical trial in adults with XLH — the final test
of a drug before federal approval.
Phase I / II
clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK in
clinical trial results reported at the American Society for
Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK in
Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58
of 78 ALK + patients responding to treatment, including 50
of 70 patients who had progressed after previous treatment with crizotinib, the
first licensed ALK inhibitor.
The
first -
of - its - kind study found the dual treatments to be safe and elicit a
clinical response in patients, according to new results from a
phase I
trial to be presented at the AACR Annual Meeting 2015 on April 19.
Sangamo biochemist Philip Gregory notes that this
Phase 1
clinical trial is the
first human test
of an entirely new class
of drug that could turn any gene on or off, depending on the disease.
Since CGP3466B has already been tested in
phase II
clinical trials to (unsuccessfully) treat Parkinson's disease and ALS, it is known to be safe for humans, but the researchers caution that many more years
of studies are needed to definitively show whether it is effective for preventing cocaine damage,
first in mice, then in humans.
«
First - line immunotherapy treatment can improve survival for subset
of lung cancer patients: Results
of phase III global
clinical trial show that 75 percent
of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»
The
first such drug, torcetrapib, was abandoned after a
phase 3
clinical trial revealed it increased the risk
of cardiovascular events and death.
Hence, a total
of 90 patients from nine centers were randomly assigned to one
of two study arms for the
phase II
clinical trial: the
first taking capsules
of olaparib (400 mg twice daily) and the other taking a combination
of the two drugs (200 mg olaparib in capsule - form twice daily and 30 mg tablets
of cediranib once daily).
PHILADELPHIA --(April 19, 2018)-- The Wistar Institute and partners at the Perelman School
of Medicine at the University
of Pennsylvania, Inovio Pharmaceuticals, and GeneOne Life Science were recognized among the Top 10
Clinical Research Achievement Awards by the
Clinical Research Forum for their ground - breaking
phase 1 DNA - based Zika vaccine research — the
first trial of a Zika vaccine in humans, which proved safe and effective.
Andy has over 10 years
of experience in
clinical trial management, specializing in early
phase,
first - in - human, global studies.
The Human
Trial is following one research team and a handful of trial patients as they move from the lab through the first two years of the Phase 1/2 clinical t
Trial is following one research team and a handful
of trial patients as they move from the lab through the first two years of the Phase 1/2 clinical t
trial patients as they move from the lab through the
first two years
of the
Phase 1/2
clinical trialtrial.
As reviewed in our previous post, AFFiRiS announced the initiation
of the
first Phase I
clinical trial of PD01A in June
of 2012.
Table 1: Selection, Design & Construction
of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction
of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction
of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction
of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction
of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction
of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored
Clinical Trials of T - Vec Table 8:
Clinical Trials of ColoAd1 Table 9:
Clinical Trials with JX - 594 Table 10:
Clinical Trials with GL - ONC1 Table 11:
Clinical Trials of CAVATAK (CVA21) Table 12:
Clinical Trials with MV - NIS Table 13: Overview
of Oncolytic Viruses by Development
Phase & Virus Family Table 14: Profile
of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design
of Oncolytic Viruses in Late Stage Development Based on Previous
Clinical Results Table 16: Approved Indications
of Immune Checkpoint Inhibitors Table 17: Active
Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned
Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned
Clinical Studies
of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern
of Transgenes in Oncolytic Viruses in Relation to Development
Phase Tables 21a and 21b: Indications and Frquency and Way
of Administration
of Oncolytic Viruses in Active and / or Positive Completed
Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development
of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio
of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests
of Major Pharma & Biotech in Oncolytic Viruses Table 25:
First Generation Oncology Virus Companies and their Sources
of Technology Table 26: Second Generation Oncology Virus Companies and their Sources
of Technology Table 27: Third Generation Oncology Virus Companies and their Sources
of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources
of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions
A University
of California at Los Angeles (UCLA) study headed by Antoni Ribas, M.D., Ph.D., is a
first - in - human
phase I
clinical trial combining adoptive cell transfer
of a T cell receptor engineered to recognize NY - ESO - 1 along with Yervoy ® (ipilimumab, anti-CTLA-4).
San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the
first stem cell - derived islet replacement therapy for the treatment
of diabetes in
clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's
Phase 1/2
clinical trial of its VC - 01TM product candidate.
Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our
first prototype inhibitors
of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages
of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to
clinical trials To evaluate novel agents in the preclinical setting and to initiate early
phase clinical trials in hematologic malignancies with focus on multiple myeloma
Its
Clinical Trials Center conducts 13 - 15 clinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea la
Clinical Trials Center conducts 13 - 15
clinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea la
clinical studies per year, and in December initiated a
Phase 2
clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea la
clinical trial of an Ebola vaccine following its groundbreaking
first - in - human testing
of the Ebola vaccine that showed efficacy in Guinea last year.
Clinical Trials Research and Billing
First in Human / Early
Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine Therapy for Hyperthyroidism: The State
of the Art Spondylodiscitis: Role
of Imaging for Diagnosis and Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity
of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging
of Lung Inflammation Standardization
of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management: Novel Therapeutics and Management Options Targeting Radionuclide Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?
Dr. Caskey and her team describe the
first in human,
phase 1
clinical trial of a
first in class fully human highly neutralizing anti-HIV monoclonal antibody.
The approval came on the heels
of the
first phase III
clinical trial ever shown to improve overall survival in patients with the disease, with median overall survival
of 10.1 months, versus 6.4 months in the control group.
Our program offers access to
Phase I
clinical trials and
First - in - children protocols available only at a very limited number
of institutions.
A so - called
Phase I
clinical trial is when a new drug or a new formulation
of a drug, or a new combination therapy for that matter, is tested in humans for the
first time.
The
first trial to take place as a result
of the CDP initiative is a
Phase I
clinical trial of GlaxoSmithKline's aurora kinase inhibitor GSK - 1070916A - a promising new drug to treat solid tumours.
Essentially, Roche has committed to paying Isis $ 30 million for the development
of its Huntington's disease drugs and the
first «
phase 1»
clinical trial in patients.
In September 2016, we announced the
first clinical application
of our GLAAS discovery platform in Sanofi's
Phase 1
clinical trial evaluating a novel therapeutic candidate for the treatment
of peanut allergy.
The
first -
of - its - kind study found the dual treatments to be safe and elicit a
clinical response in patients, according to new results from a
phase I
trial to be presented at the AACR Annual Meeting 2015 on Sunday, April 19 (Abstract #CT137).
Phase zero — the
first example
of a new pre-
phase-I
clinical trial came from the National Cancer Institute for a drug in Abbott's pipelinine.